Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $131.86 Average PT from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has earned a consensus rating of "Buy" from the seven research firms that are presently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $131.86.

Several brokerages have weighed in on LNTH. Truist Financial reaffirmed a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective on the stock. JMP Securities cut their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a report on Thursday, November 7th. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday. They issued a "buy" rating and a $143.00 target price for the company.

Lantheus Trading Down 2.9 %

NASDAQ LNTH traded down $2.65 on Friday, hitting $89.29. 2,181,956 shares of the company's stock traded hands, compared to its average volume of 1,019,316. The firm has a market capitalization of $6.21 billion, a PE ratio of 14.86 and a beta of 0.45. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The firm's 50-day moving average price is $96.63 and its two-hundred day moving average price is $98.18.

Institutional Investors Weigh In On Lantheus

Several institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. Tidal Investments LLC increased its stake in Lantheus by 25.2% during the 3rd quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider's stock worth $1,934,000 after buying an additional 3,547 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the third quarter worth approximately $25,000. World Investment Advisors LLC acquired a new stake in shares of Lantheus in the third quarter worth approximately $60,000. Hohimer Wealth Management LLC purchased a new stake in shares of Lantheus during the third quarter worth approximately $250,000. Finally, Coldstream Capital Management Inc. acquired a new position in Lantheus in the 3rd quarter valued at $230,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.